# Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.

> **NCT05575505** · PHASE2 · RECRUITING · sponsor: **Tanta University** · enrollment: 44 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

- **DRUG:** Pentoxifylline 400 MG

## Key facts

- **NCT ID:** NCT05575505
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-02
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05575505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05575505, "Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05575505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*